Lauran Neergaard, Medical Writer, MDT/AP
If there were ever a disease that tempts scientists to reach for a permanent fix, it is high cholesterol. Pop a pill every day for decades – or flip a genetic switch once and be done with it? That is the tantalizing question behind a new wave of gene-editing research.
Two biotech companies are testing whether CRISPR, the Nobel Prize-winning gene-editing tool, can permanently lower artery-clogging LDL cholesterol. The idea is straightforward: switch off specific liver genes that drive cholesterol production. In practice, it is early days – and caution is not optional.
Heart disease remains the leading killer globally. Too much LDL builds plaque in arteries, raising the risk of heart attacks and strokes. Statins have long been the backbone of treatment. They are cheap and effective. Yet not everyone reaches target levels, and some patients abandon them because of side effects or fatigue from lifelong medication.
Gene-editing aims to change that equation.
Researchers have long known that some people naturally carry mutations that disable certain cholesterol-related genes and enjoy strikingly low LDL levels without harm. Two genes in particular, ANGPTL3 and PCSK9, have drawn attention. People with loss-of-function mutations in these genes tend to have low cholesterol and reduced heart disease risk. Nature, in other words, has already run the experiment.
Now scientists are trying to replicate that outcome deliberately.
In one small study, 15 high-risk adults received a single infusion delivering CRISPR machinery to the liver to disable the ANGPTL3 gene. Within weeks, those given the highest dose saw LDL and triglycerides fall by roughly 50 percent. A separate early trial targeting PCSK9 reported similar reductions.
These are eye-catching numbers. A one-time treatment cutting “bad” cholesterol in half sounds like cardiology’s moonshot. Unsurprisingly, doctors involved report strong patient interest.
But let’s keep perspective. These trials involve only a few dozen people and are designed primarily to test safety, not long-term effectiveness. Gene editing, unlike a pill you can stop tomorrow, is intended to be permanent.
That permanence is both the promise and the peril.
CRISPR-based therapies are still new. Long-term data remain limited. Delivering the editing tool to the liver can trigger inflammation. Off-target edits – unintended genetic changes – remain a concern. And while people born with naturally disabled ANGPTL3 or PCSK9 genes appear healthy, that does not guarantee identical outcomes decades later.
For now, these studies focus on patients at very high risk – people whose cholesterol remains dangerously elevated despite maximum therapy.
For the broader public, the message is less glamorous: take your medicine.
Lifestyle changes still matter. Diet, exercise, maintaining a healthy weight, quitting smoking and controlling blood pressure and diabetes remain central to heart health. Statins and other cholesterol-lowering drugs are proven to reduce heart attacks and save lives.
Gene editing could one day transform prevention, particularly for people with inherited severe cholesterol disorders. A single intervention replacing decades of pills would be revolutionary. Yet revolutions in medicine are built on years of data, not headlines.
So yes, the science is exciting. It hints at a future where heart disease prevention might be one-and-done. But until larger, longer trials confirm safety and durability, CRISPR remains a promising experiment – not a prescription.
In the meantime, the advice still stands. Eat better. Move more. Monitor your numbers. And if your doctor prescribes a statin, swallow it.
[Abridged]
No Comments